Psychological Issues and Evaluation for Patients Undergoing Implantable Technology

Doleys, Daniel M.

doi:10.1016/b978-0-12-374248-3.00009-4

Cited by 4 publications

(2 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another major component in determining eligibility is psychological attitude towards the treatment. There is the postulation that the belief or willingness in the treatment to work dramatically affects outcomes and duration of relief (16,17).…”

Section: Patient Selectionmentioning

confidence: 99%

Peripheral Neuromodulation for the Management of Headache

et al. 2020

View full text Add to dashboard Cite

Context: Neuromodulation is an expanding field of study for headache treatment to reduce pain by targeting structures within the nervous system commonly involved in headache pathophysiology, such as the vagus nerve (VNS), occipital nerves, or sphenopalatine ganglion (SPG) for stimulation. Pharmaceutical medical therapies for abortive and prophylactic treatment, such as triptans, NSAIDs, beta-blockers, TCAs, and antiepileptics, are effective for some individuals, but the role that technology plays in investigating other therapeutic modalities is essential. Peripheral neuromodulation has gained popularity and FDA approval for use in treating certain headaches and migraine headache conditions, particularly in those who are refractory to treatment. Early trials found FDA approved neurostimulatory implant devices, including Cephaly and SpringTMS, improved patient-oriented outcomes with reductions in headaches per month (frequency) and severity. Evidence Acquisition: This was a narrative review. The sources for this review are as follows: Searching on PubMed, Google Scholar, Medline, and ScienceDirect from 1990 - 2019 using keywords: Peripheral Neuromodulation, Headache, vagus nerve, occipital nerves, sphenopalatine ganglion. Results: The first noninvasive neurostimulator device approved for migraine treatment was the Cefaly device, an external trigeminal nerve stimulation device (e-TNS) that transcutaneously excites the supratrochlear and supraorbital branches of the ophthalmic nerve. The second noninvasive neurostimulation device receiving FDA approval was the single-pulse transcranial magnetic stimulator, SpringTMS, positioned at the occiput to treat migraine with aura. GammaCore is a handheld transcutaneous vagal nerve stimulator applied directly to the neck at home by the patient for treatment of cluster headache (CH) and migraine. Several other devices are in development for the treatment of headaches and target headache evolution at different levels and inputs. The Scion device is a caloric vestibular stimulator (CVS) which interfaces with the user through a set of small cones resting in the ear canal on either side and held in place by modified over-ear headphones. The pulsante SPG Microstimulator is a patient-controlled device implanted in the patient’s upper jaw via an hour-long oral procedure to target the sphenopalatine ganglion. The occipital nerve stimulator (ONS) is an invasive neuromodulation device for headache treatment that consists of an implanted pulse generator on the chest wall connected to a subcutaneous lead with 4 - 8 electrodes that is tunneled the occiput. Conclusions: The aim of this review is to provide a comprehensive overview of the efficacy, preliminary outcomes, and limitations of neurostimulatory implants available for use in the US and those pending further development.

show abstract

Section: Patient Selectionmentioning

confidence: 99%

Peripheral Neuromodulation for the Management of Headache

et al. 2020

View full text Add to dashboard Cite

show abstract

“…While clinical experience by physicians and psychologists has affirmed this approach, there are a limited number of systematic and controlled studies with good evidence for the fact. Although the literature describes various assessment approaches for obtaining the patient history, performing the mental status examination, and administering standardized psychological testing, there are no standardized procedures (43,45,118).…”

Section: Psychological Evaluation During the Screening And Trialing Pmentioning

confidence: 99%